Clinical trialNCT05873686RecruitingPhase 1Interventional

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

SponsorNuvectis Pharma, Inc.Enrollment140Advanced Solid TumorMesotheliomaNSCLC (Non-small Cell Lung Cancer)Non-Small Cell Squamous Lung CancerNon-small Cell Lung AdenocarcinomaRenal Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Gerald Falchook, MD
Sarah Cannon Cancer Institute, HealthOne Denver
Principal Investigator
clinicaltrials.gov ↗
Udai Banerji, Prof
Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United Kingdom

Western General Hospital - Nhs Lothian
Edinburgh, United Kingdom
Completed
the Royal Marsden Nhs Foundation and Trust
London, United Kingdom
Completed

United States

Mayo Clinic
Phoenix, Arizona, United States
Recruiting
Uc San Diego Moores Cancer Center
La Jolla, California, United States
Recruiting
Sarah Cannon Research Institute at Healthone
Denver, Colorado, United States
Recruiting
Mayo Clinic
Jacksonville, Florida, United States
Recruiting
University of Chicago
Chicago, Illinois, United States
Recruiting
Mayo Clinic Rochester
Rochester, Minnesota, United States
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Recruiting
Cleveland Clinic
Cleveland, Ohio, United States
Recruiting
Oregon Health and Science University
Portland, Oregon, United States
Recruiting
Next Oncology Houston
Houston, Texas, United States
Recruiting
the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Recruiting
Next Oncology Dallas
Irving, Texas, United States
Recruiting
Next Oncology Virginia
Fairfax, Virginia, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

NXP900

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 26 Oct 2023
Primary completion: 31 Mar 2027
Completion: 31 Jul 2027
Last update posted: 9 Jul 2026
Registered enrollment: 140
Registry id: NCT05873686

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.